Antimutagenic potential of Liv52 by ames salmonella/mammalian

Microsome mutagenicity assay

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Objective: Liv52, a nontoxic herbal preparation is reported to be clinically active in hepatotoxicity and a wide range of hepatic disorders. This study was undertaken to evaluate the mutagenic/antimutagenic potential of Liv52 using Salmonella mutagenicity test. Methods: Ames Salmonella/Mammalian - microsome mutagenicity test was used to evaluate the mutagenic or antimutagenic potential of Liv52. Salmonella typhimurium tester strains TA1537, TA1538, TA100, and TA102 were used for mutagenicity testing. The antimutagenicity study was carried out in tester strains TA1538 and TA100 against various standard mutagens with and without metabolic activation. Results: Liv52 did not show any mutagenic potential both with and without metabolic activation, whereas in TA1538 and TA 100 tester strains, Liv52 showed 48.4% and 47.2% of inhibition of his+ revertants induced by 4-nitro-O-phenylenediamine, respectively. Further with metabolic activation in TA1538, Liv52 showed 99.8%, 99.8%, and 100% inhibition of his+ revertants induced by 2-aminofluorene, 2-anthranine, and cigarette smoke condensate, respectively. In TA100 maximum of 100%, 100%, 97.7%, and 100% inhibition of his+ revertants induced by 2-aminofluorene, 2-anthranine, benzo(a)pyrene, and cigarette smoke condensate, respectively, were observed. A significant enhancement of inhibition of his+ revertants induced by all the above said mutagens were observed in preincubation modification method. Conclusion: Liv52 was found to be nonmutagenic in Salmonella assay, whereas manifested the antimutagenic potential both with and without metabolic activation. The enhanced antimutagenic activity of Liv52 on preincubation indicates that the antimutagenic factor(s) may be desmutagenic in nature. The exact mechanism by which Liv52 exerts antimutagenic potential is not known. The possibility of having diverse antimutagenic factors in Liv52 which act by different mechanisms are strongly indicated.

Original languageEnglish
Pages (from-to)227-282
Number of pages56
JournalAsian Journal of Pharmaceutical and Clinical Research
Volume10
Issue number3
DOIs
Publication statusPublished - 01-03-2017

Fingerprint

Microsomes
Salmonella
Mutagenicity Tests
Mutagens
Smoke
Tobacco Products
Plant Preparations
Phenylenediamines
Benzo(a)pyrene
Salmonella typhimurium
Metabolic Activation
Liver
2-aminofluorene

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmaceutical Science
  • Pharmacology (medical)

Cite this

@article{9287389e4c7647078e69ad89888dfb94,
title = "Antimutagenic potential of Liv52 by ames salmonella/mammalian: Microsome mutagenicity assay",
abstract = "Objective: Liv52, a nontoxic herbal preparation is reported to be clinically active in hepatotoxicity and a wide range of hepatic disorders. This study was undertaken to evaluate the mutagenic/antimutagenic potential of Liv52 using Salmonella mutagenicity test. Methods: Ames Salmonella/Mammalian - microsome mutagenicity test was used to evaluate the mutagenic or antimutagenic potential of Liv52. Salmonella typhimurium tester strains TA1537, TA1538, TA100, and TA102 were used for mutagenicity testing. The antimutagenicity study was carried out in tester strains TA1538 and TA100 against various standard mutagens with and without metabolic activation. Results: Liv52 did not show any mutagenic potential both with and without metabolic activation, whereas in TA1538 and TA 100 tester strains, Liv52 showed 48.4{\%} and 47.2{\%} of inhibition of his+ revertants induced by 4-nitro-O-phenylenediamine, respectively. Further with metabolic activation in TA1538, Liv52 showed 99.8{\%}, 99.8{\%}, and 100{\%} inhibition of his+ revertants induced by 2-aminofluorene, 2-anthranine, and cigarette smoke condensate, respectively. In TA100 maximum of 100{\%}, 100{\%}, 97.7{\%}, and 100{\%} inhibition of his+ revertants induced by 2-aminofluorene, 2-anthranine, benzo(a)pyrene, and cigarette smoke condensate, respectively, were observed. A significant enhancement of inhibition of his+ revertants induced by all the above said mutagens were observed in preincubation modification method. Conclusion: Liv52 was found to be nonmutagenic in Salmonella assay, whereas manifested the antimutagenic potential both with and without metabolic activation. The enhanced antimutagenic activity of Liv52 on preincubation indicates that the antimutagenic factor(s) may be desmutagenic in nature. The exact mechanism by which Liv52 exerts antimutagenic potential is not known. The possibility of having diverse antimutagenic factors in Liv52 which act by different mechanisms are strongly indicated.",
author = "Manipura Radhakrishna and Hedge, {M. J.}",
year = "2017",
month = "3",
day = "1",
doi = "10.22159/ajpcr.2017.v10i3.16148",
language = "English",
volume = "10",
pages = "227--282",
journal = "Asian Journal of Pharmaceutical and Clinical Research",
issn = "0974-2441",
publisher = "Innovare Academics Sciences Pvt. Ltd",
number = "3",

}

Antimutagenic potential of Liv52 by ames salmonella/mammalian : Microsome mutagenicity assay. / Radhakrishna, Manipura; Hedge, M. J.

In: Asian Journal of Pharmaceutical and Clinical Research, Vol. 10, No. 3, 01.03.2017, p. 227-282.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Antimutagenic potential of Liv52 by ames salmonella/mammalian

T2 - Microsome mutagenicity assay

AU - Radhakrishna, Manipura

AU - Hedge, M. J.

PY - 2017/3/1

Y1 - 2017/3/1

N2 - Objective: Liv52, a nontoxic herbal preparation is reported to be clinically active in hepatotoxicity and a wide range of hepatic disorders. This study was undertaken to evaluate the mutagenic/antimutagenic potential of Liv52 using Salmonella mutagenicity test. Methods: Ames Salmonella/Mammalian - microsome mutagenicity test was used to evaluate the mutagenic or antimutagenic potential of Liv52. Salmonella typhimurium tester strains TA1537, TA1538, TA100, and TA102 were used for mutagenicity testing. The antimutagenicity study was carried out in tester strains TA1538 and TA100 against various standard mutagens with and without metabolic activation. Results: Liv52 did not show any mutagenic potential both with and without metabolic activation, whereas in TA1538 and TA 100 tester strains, Liv52 showed 48.4% and 47.2% of inhibition of his+ revertants induced by 4-nitro-O-phenylenediamine, respectively. Further with metabolic activation in TA1538, Liv52 showed 99.8%, 99.8%, and 100% inhibition of his+ revertants induced by 2-aminofluorene, 2-anthranine, and cigarette smoke condensate, respectively. In TA100 maximum of 100%, 100%, 97.7%, and 100% inhibition of his+ revertants induced by 2-aminofluorene, 2-anthranine, benzo(a)pyrene, and cigarette smoke condensate, respectively, were observed. A significant enhancement of inhibition of his+ revertants induced by all the above said mutagens were observed in preincubation modification method. Conclusion: Liv52 was found to be nonmutagenic in Salmonella assay, whereas manifested the antimutagenic potential both with and without metabolic activation. The enhanced antimutagenic activity of Liv52 on preincubation indicates that the antimutagenic factor(s) may be desmutagenic in nature. The exact mechanism by which Liv52 exerts antimutagenic potential is not known. The possibility of having diverse antimutagenic factors in Liv52 which act by different mechanisms are strongly indicated.

AB - Objective: Liv52, a nontoxic herbal preparation is reported to be clinically active in hepatotoxicity and a wide range of hepatic disorders. This study was undertaken to evaluate the mutagenic/antimutagenic potential of Liv52 using Salmonella mutagenicity test. Methods: Ames Salmonella/Mammalian - microsome mutagenicity test was used to evaluate the mutagenic or antimutagenic potential of Liv52. Salmonella typhimurium tester strains TA1537, TA1538, TA100, and TA102 were used for mutagenicity testing. The antimutagenicity study was carried out in tester strains TA1538 and TA100 against various standard mutagens with and without metabolic activation. Results: Liv52 did not show any mutagenic potential both with and without metabolic activation, whereas in TA1538 and TA 100 tester strains, Liv52 showed 48.4% and 47.2% of inhibition of his+ revertants induced by 4-nitro-O-phenylenediamine, respectively. Further with metabolic activation in TA1538, Liv52 showed 99.8%, 99.8%, and 100% inhibition of his+ revertants induced by 2-aminofluorene, 2-anthranine, and cigarette smoke condensate, respectively. In TA100 maximum of 100%, 100%, 97.7%, and 100% inhibition of his+ revertants induced by 2-aminofluorene, 2-anthranine, benzo(a)pyrene, and cigarette smoke condensate, respectively, were observed. A significant enhancement of inhibition of his+ revertants induced by all the above said mutagens were observed in preincubation modification method. Conclusion: Liv52 was found to be nonmutagenic in Salmonella assay, whereas manifested the antimutagenic potential both with and without metabolic activation. The enhanced antimutagenic activity of Liv52 on preincubation indicates that the antimutagenic factor(s) may be desmutagenic in nature. The exact mechanism by which Liv52 exerts antimutagenic potential is not known. The possibility of having diverse antimutagenic factors in Liv52 which act by different mechanisms are strongly indicated.

UR - http://www.scopus.com/inward/record.url?scp=85014748453&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85014748453&partnerID=8YFLogxK

U2 - 10.22159/ajpcr.2017.v10i3.16148

DO - 10.22159/ajpcr.2017.v10i3.16148

M3 - Article

VL - 10

SP - 227

EP - 282

JO - Asian Journal of Pharmaceutical and Clinical Research

JF - Asian Journal of Pharmaceutical and Clinical Research

SN - 0974-2441

IS - 3

ER -